<i>N</i>-(2-Formylphenyl)-4-toluenesulfonamide: a second monoclinic polymorph

Murugavel, S.; Manikandan, N.; Kannan, D.; Bakthadoss, Manickam

doi:10.1107/s1600536812009403

Cited by 2 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For related structures, see: Murugavel et al (2012); Zhang et al (2010). Sulfonamides, which are already known as sulfa drugs, are an important class of compounds in the field of chemistry, biology and pharmacology.…”

Section: S1 Structural Commentarymentioning

confidence: 99%

4-Methyl-N-{2-[(E)-3-oxo-3-phenylprop-1-en-1-yl]phenyl}benzenesulfonamide

Kim

2014

Acta Cryst E

View full text Add to dashboard Cite

Key indicators: single-crystal X-ray study; T = 200 K; mean (C-C) = 0.004 Å; R factor = 0.057; wR factor = 0.154; data-to-parameter ratio = 18.7.In the title compound, C 22 H 19 NO 3 S, the terminal phenyl and methylphenyl rings are twisted by 37.35 (12) and 49.08 (13) , respectively, to the central benzene ring. In the crystal, molecules are linked by classical N-HÁ Á ÁO hydrogen bonds and weak C-HÁ Á ÁO hydrogen bonds into a three-dimensional supramolecular network. Related literature

show abstract

Section: S1 Structural Commentarymentioning

confidence: 99%

4-Methyl-N-{2-[(E)-3-oxo-3-phenylprop-1-en-1-yl]phenyl}benzenesulfonamide

Kim

2014

Acta Cryst E

View full text Add to dashboard Cite

show abstract

Solid‐State Form Screen of Cardiosulfa and Its Analogues

Kumar

Rana

Nangia

2013

Chemistry An Asian Journal

View full text Add to dashboard Cite

Cardiosulfa is a biologically active sulfonamide molecule that was recently shown to induce abnormal heart development in zebrafish embryos through activation of the aryl hydrocarbon receptor (AhR). The present report is a systematic study of solid-state forms of cardiosulfa and its biologically active analogues that belong to the N-(9-ethyl-9H-carbazol-3-yl)benzene sulfonamide skeleton. Cardiosulfa (molecule 1; R(1) = NO2, R(2) = H, R(3) = CF3), molecule 2 (H, H, CF3), molecule 3 (CF3, H, H), molecule 4 (NO2, H, H), molecule 5 (H, CF3, H), and molecule 6 (H, H, H) were synthesized and subjected to a polymorph search and solid-state form characterization by X-ray diffraction, differential scanning calorimetry (DSC), variable-temperature powder X-ray diffraction (VT-PXRD), FTIR, and solid-state (ss) NMR spectroscopy. Molecule 1 was obtained in a single-crystalline modification that is sustained by N-H⋅⋅⋅π and C-H⋅⋅⋅O interactions but devoid of strong intermolecular N-H⋅⋅⋅O hydrogen bonds. Molecule 2 displayed a N-H⋅⋅⋅O catemer C(4) chain in form I, whereas a second polymorph was characterized by PXRD. The dimorphs of molecule 3 contain N-H⋅⋅⋅π and C-H⋅⋅⋅O interactions but no N-H⋅⋅⋅O bonds. Molecule 4 is trimorphic with N-H⋅⋅⋅O catemer in form I, and N-H⋅⋅⋅π and C-H⋅⋅⋅O interactions in form II, and a third polymorph was characterized by PXRD. Both polymorphs of molecule 5 contain the N-H⋅⋅⋅O catemer C(4) chain, whereas the sulfonamide N-H⋅⋅⋅O dimer synthon R2(2)(8) was observed in polymorphs of 6. Differences in the strong and weak hydrogen-bond motifs were correlated with the substituent groups, and the solubility and dissolution rates were correlated with the conformation in the crystal structure of 1-6. Higher solubility compounds, such as 2 (10.5 mg mL(-1)) and 5 (4.4 mg mL(-1)), adopt a twisted confirmation, whereas less-soluble 1 (0.9 mg mL(-1)) is nearly planar. This study provides practical guides for functional-group modification of drug lead compounds for solubility optimization.

show abstract

N-(2-Formylphenyl)-4-toluenesulfonamide: a second monoclinic polymorph

Cited by 2 publications

References 10 publications

4-Methyl-N-{2-[(E)-3-oxo-3-phenylprop-1-en-1-yl]phenyl}benzenesulfonamide

4-Methyl-N-{2-[(E)-3-oxo-3-phenylprop-1-en-1-yl]phenyl}benzenesulfonamide

Solid‐State Form Screen of Cardiosulfa and Its Analogues

Contact Info

Product

Resources

About